What is Paramyxovirus technology?
Crucell’s Paramyxovirus technology is a novel vaccine
delivery system based on recombinant
measles vectors: gene transport vehicles made from modified measles virus. The RNA
code for an antigen—the part of a pathogen
that is recognized by the immune system—can be inserted into such a vector
to make a vaccine.
- Recombinant measles vectors carrying RNA encoding for antigenic proteins from other human pathogens can be manufactured to high titers using production and purification protocols established for the manufacture of classical measles vaccine.
- The recombinant measles vaccine on which the vector is based has an excellent safety record, as the classical measles vaccine has been safely administered to many millions of people over the past decades.
- Recombinant measles vectors induce strong and long-lasting immune responses against the antigens they present to the immune system.